A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

NCT04566601 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Borderline Personality Disorder

Interventions

DRUG: BI 1358894
DRUG: Placebo

Sponsor

Boehringer Ingelheim